@TheRegenBio We need answers! What happen to the $452,000 that was raised in the Reg A offering and another $202,000 raised from two promissory notes back in July and August of 2025?
@TheRegenBio Koos don't even think of fighting shorts without canceling Reg A. The stock will get decimated unless your prepared to buy the entire float. Be Patient. Wait for the FDA grant to be approved than precede with fighting shorts. You made too many mistakes with impulsive financings.
@TheRegenBio Cancel the $.01 Reg A offering. Wait for the FDA Grant. Your own words:
"As far as the grant opportunity is concerned, I’ve never seen a grant more suited for a product like HemaXellerate or a product more suited for a grant. I’m confident and excited regarding these developments
$RGBP a biotech trading at a 3.6 million dollar market cap going into human phase 1 clinical trials in a billion dollar industry with a portfolio of over 20 patents (cancer therapy related) should be trading at what market cap? 50 million ? 100 Million? 250 million ?
$RGBP $RGBPP
Regen BioPharma, Inc. to Discuss Plans to Move Forward with HemaXellerate into Clinical Phase 1 at the Emerging Growth Conference on April 4, 2024
https://t.co/532i4H37Bh.
$RGBP Regen BioPharma Inc. will be presenting at the Emerging Growth conference on Nov 1, 2023, 2:20 - 2:50. David Koos, President / CEO & Harry M. Lander, Ph.D. Senior Scientific Consultant. 30 Minutes? More time = More updates? 🤞🏽🚀https://t.co/Vp2ULqqzBd…
$RGBP “We now have a sound scientific basis to pursue designing #T-cells which can tamp down on the uncontrolled immune activation seen in multiple #autoimmune disorders," says Dr. Harry Lander, CSC to @TheRegenBio@ProPennyPicks@SCStocks@stockzeus
https://t.co/5Ghk8xJio7
Stock Symbol $RGBP @TheRegenBio News: Regen BioPharma, Inc. Receives Second Phase Confirmatory Data on its Duracar CAR-T Cell Therapy Program #mRNA#autoimmunity#FDA#pfizer $PFE #NEWS
https://t.co/NGx2sBVLnx $TLRY $OGI $LFLY $ACB $MAPS $IIPR $VRNOF
$RGBP $RGBPP Regen BioPharma, Inc. Receives Second Phase Confirmatory Data on its Duracar CAR-T Cell Therapy Program… The kind of news longs have been waiting/hoping for. @TheRegenBio taking the right steps to gain some investors trust back. 🐂 https://t.co/0zD1SknDgR
$RGBP Receives Second Phase Confirmatory Data on its Duracar CAR-T Cell Therapy Program- "We now have a sound scientific basis to pursue designing T cells which can tamp down on the uncontrolled immune activation seen in multiple #autoimmune disorders"
https://t.co/wPRfN0XU8K
$RGBP $RGBPP
We are delighted to get our first dataset from an independent CRO which shows that the CAR T-cells are doing what we expect and look forward to the next set of data which will inform us about the disease areas, whether autoimmunity or cancer, we will focus on